Boots Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 31-08-2024
- Paid Up Capital ₹ 0.50 M
as on 31-08-2024
- Company Age 15 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -27.91%
(FY 2023)
- Profit -32.59%
(FY 2023)
- Ebitda -15.18%
(FY 2023)
- Net Worth 20.49%
(FY 2023)
- Total Assets 3.43%
(FY 2023)
About Boots Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Chandulal Parmar, Dimple Parmar, Parmar Rohan, and Two other members serve as directors at the Company.
- CIN/LLPIN
U85120TN2009PLC072846
- Company No.
072846
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
09 Sep 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Krishnagiri, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Boots Lifesciences Limited offer?
Boots Lifesciences Limited offers a wide range of products and services, including Vitamins & Supplements, Mineral Supplements.
Who are the key members and board of directors at Boots Lifesciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dimple Parmar  | Managing Director | 09-Sep-2009 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chandulal Parmar | Director | 07-Jun-2024 | Current |
| Parmar Rohan | Director | 16-Jul-2018 | Current |
| Sidhanth Parmar | Director | 15-May-2024 | Current |
| Jigar Parmar | Director | 15-May-2024 | Current |
Financial Performance of Boots Lifesciences.
Boots Lifesciences Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.91% decrease. The company also saw a substantial fall in profitability, with a 32.59% decrease in profit. The company's net worth Soared by an impressive increase of 20.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Boots Lifesciences?
In 2023, Boots Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Boots Lifesciences?
Unlock and access historical data on people associated with Boots Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Boots Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Boots Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
